TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% ...

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease (one in which the immune system attacks healthy cells) that ...

The psoriasis treatment that works for you initially may not continue working long term. Some benefits of trying a new treatment can include improved skin clearance, fewer side effects, and saving ...